FDA Adverse Event Malfunction Summary report: N

SERACLONE ANTI-K (KEL2)

MDR report key: 2527081 · Received March 18, 2010

Report

Report Number
9610824-2010-00004
Event Type
Malfunction
Date Received
March 18, 2010
Date of Event
March 1, 2010
Report Date
March 17, 2010
Manufacturer
BIOTEST MEDICAL DIAGNOSTICS GMBH
Product Code
KSZ
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
GM
Reporter Occupation
OTHER

Narratives

Additional Manufacturer Narrative · 1

A FIELD SAFETY CORRECTIVE ACTION WAS INITIATED (NOT IN THE U.S.). THE AFFECTED BATCHES ARE NOT ON THE U.S. MARKET, AS THE MENTIONED CATALOG NUMBER IS USED FOR NON-US-PRODUCT ONLY. STN#: 125232.

Description of Event or Problem · 1

THE CUSTOMER COMPLAINED THAT THREE PATIENTS WERE TYPED FALSE POSITIVE USING THE BLOOD GROUPING REAGENT SERACLONE ANTI-K (KEL2). THE CUSTOMER SENT US TWO OF THREE PATIENT SAMPLES. THESE PATIENT SAMPLES WERE TESTED WITH THE RETENTION SAMPLE OF THE COMPLAINED LOT IN THE QUALITY CONTROL LABORATORY ACCORDING TO THE INSTRUCTIONS FOR USE. WE CONFIRMED THE FALSE POSITIVE REACTIONS OF THE CUSTOMER. THE CUSTOMER WAS AWARE OF THE FALSE POSITIVE REACTIONS BECAUSE HE TESTED THE SAMPLES WITH TWO DIFFERENT ANTI-K (KEL2) REAGENTS ACCORDING TO THE (B)(6) RULES "(B)(4)." THE AFFECTED LOT (B)(4) WAS FILLED OF THE BULK LOT 84707. A SECOND LOT, THE LOT (B)(4), WAS ALSO FILLED OF THE BULK LOT (B)(4). ALTHOUGH WE DID NOT RECEIVE ANY COMPLAINT FOR LOT (B)(4), THE BATCH WAS TESTED AND REACTED ALSO FALSE POSITIVE. ALBA BIOSCIENCE LIMITED, THE SUPPLIER OF THE BULK REAGENT SERACLONE ANTI-K (KEL2) WAS INFORMED AND CONFIRMED THE FALSE POSITIVE REACTIONS. AS A CONSEQUENCE OF THE CONFIRMED FALSE POSITIVE REACTIONS BOTH LOTS (B)(4) WERE BLOCKED AND A FIELD SAFETY CORRECTIVE ACTION WAS INITIATED. THE AFFECTED BATCHES ARE NOT ON THE U.S MARKET, AS THE MENTIONED CATALOG NUMBER IS USED FOR NON-US-PRODUCT ONLY.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 SERACLONE ANTI-K (KEL2) SERACLONE KSZ BIOTEST MEDICAL DIAGNOSTICS GMBH 1847071

Patients

Seq Age Sex Outcome Treatment
1